In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
Novartis has announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta (ofatumumab) treatment for up to six years in recently diagnosed treatment-naïve people living with relapsing multiple sclerosis (RMS). 17 April 2024
Pharmaceutical
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Fintepla (fenfluramine) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. 17 April 2024
Pharmaceutical
Medicare beneficiaries in the USA are facing greater access restrictions on their lifesaving medicines, according to a study by the Schaeffer Center at the University of Southern California. 17 April 2024
Biotechnology
A change of therapeutic focus, a full rebrand and a major cash injection will shake things up considerably at Massachusetts, USA-based Cullinan Therapeutics. 17 April 2024
Biotechnology
North Carolina, USA-based KBI Biopharma has appointed Jean-Baptiste Agnus as chief business officer, joining the company’s executive team. 17 April 2024
Generics
The Russian government is considering designing additional measures aimed at creating conditions for the growth of domestic pharmaceutical market during the period of 2024-2025, reports The Pharma Letter’s local correspondent. 17 April 2024
Biotechnology
Innovio Pharmaceuticals has announced plans to raise $36 million in a share sale. 16 April 2024
Pharmaceutical
France-based Medincell, a biopharma developing long-acting injectable drugs in many therapeutic areas, has announced a collaboration with US drugmaker AbbVie. 16 April 2024
Pharmaceutical
US healthcare giant Johnson & Johnson has announced its financial results for the first quarter of 2024. 16 April 2024
Biotechnology
US clinical-stage cell therapy developer Vittoria Biotherapeutics has announced that Keith Westby has joined the company as its inaugural chief operating officer (COO). 16 April 2024
Pharmaceutical
German family-owned drugmaker Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned, along with its full-year 2023 financial results. 16 April 2024
Pharmaceutical
Having recently gained US regulatory approval for its Fabhalta (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), Swiss pharma giant Novartis is now arming itself with clinical data for a new indication. 16 April 2024
Biosimilars
Germany’s Fresenius - via its operating company Fresenius Kabi - has announced the immediate US availability of Tyenne (tocilizumab-aazg), a biosimilar of Roche’s Actemra (tocilizumab). 16 April 2024
Biotechnology
Japanese drugmaker Astellas expects to book an impairment charge of 70 billion yen ($453 million) in the fourth quarter of Japan’s 2023 fiscal year, which ended last month. 16 April 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals recently unveiled final data from its Phase II SHASTA-2 clinical trial for plozasiran, previously recognized as ARO-APOC3. 16 April 2024
Pharmaceutical
USA-based rare seizure specialist Marinus Pharmaceuticals saw its shares crash, falling nearly 83% to $1.36, after it revealed that a trial failed to meet early stopping criteria. 16 April 2024
Biotechnology
A new investment fund has been launched by Regeneron, with half a billion dollars to spend on biotech innovation. 16 April 2024
Biotechnology
UK pharma major AstraZeneca has notched up another clinical success for its already blockbuster cancer drug Imfinzi (durvalumab) in biliary tract cancer. 16 April 2024
Pharmaceutical
The US medicines regulator has established a new Center for Clinical Trial Innovation (C3TI). 16 April 2024
Pharmaceutical
In a significant stride towards addressing the challenge of meningococcal-B disease, Serum Institute of India (SII) and the University of Oxford, UK, have formalized a technology license agreement negotiated by Oxford University Innovation. 16 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze